XXXX as Locus of Cancer Unknown Primary Site.

@entity706 @entity6872 @entity5 @entity584 @entity1582 @entity1778 @entity519 @entity3
UNASSIGNED: Cancer of unknown primary site is a @entity3 developed by the positive feedback loops of @entity5 forming extreme @entity5 . Such robustness occurs only in metastatic @entity5 or in @entity706 , @entity1582 , @entity6872 or @entity1778 . However, when it develops in @entity5 , @entity519 microenvironment generates positive feedback loops which hyperactivate @entity584 locus, forming extreme robustness that forcing @entity5 cells to migrate to the distant site, but @entity5 loosing that property or remains silent. Positive loops are the force and principal mechanism of @entity3 development. A @entity5 cell is converted normal cell. Conversion occurs at the @entity584 genomic locus. Thus, @entity5 is genomic disease rather than disease of the specific organs. Targeting such locus by the locus chemotherapy (redox balance change) rather than by organ specific therapy results in conversion of positive loops into negative and disappearance of extreme robustness and malignant phenotype of the @entity5 unknown primary origin. This article is protected by copyright. All rights reserved.
